NIOX GroupCSSPF 77 5-Year Yield-on-Cost % is 2.73 as of Jun. 29, 2026, which is 74% above its 10-year median of 1.57. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 329 Medical Devices & Instruments companies, NIOX Group ranks better than 54.71% on this metric.
NIOX Group's yield on cost for the quarter that ended in Dec. 2025 was 2.73.
The historical rank and industry rank for NIOX Group's 5-Year Yield-on-Cost % or its related term are showing as below:
CSSPF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.32 Med: 1.57 Max: 2.73
Current: 2.73
During the past 13 years, NIOX Group's highest Yield on Cost was 2.73. The lowest was 1.32. And the median was 1.57.
CSSPF's 5-Year Yield-on-Cost % is ranked better than 54.71% of 329
companies
in the Medical Devices & Instruments industry
Industry Median: 2.39
vs CSSPF: 2.73
NIOX Group (OTCPK:CSSPF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
NIOX Group 5-Year Yield-on-Cost % Related Terms
CSSPF vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, NIOX Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where NIOX Group's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of NIOX Group is calculated as
NIOX Group (CSSPF) has a 5-Year Yield-on-Cost % of 2.73 as of Jun. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on NIOX Group and its competitors. This is 74% above median its historical median of 1.57. Over the past decade, NIOX Group's 5-Year Yield-on-Cost % has ranged from 1.32 to 2.73. According to the industry distribution chart, NIOX Group ranks #149 out of 329 companies in the Medical Devices & Instruments industry, placing it in the top 45.3%.
Is NIOX Group's 5-Year Yield-on-Cost % too high?
NIOX Group's current 5-Year Yield-on-Cost % of 2.73 is 74% above median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 2.73. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.39. NIOX Group's value of 2.73 is 14.2% above this industry median. Based on the distribution chart, NIOX Group ranks #149 out of 329 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #149 out of 329 companies for 5-Year Yield-on-Cost %. This puts NIOX Group in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. NIOX Group's value of 2.73 is 14.2% above this benchmark. Historically, NIOX Group's own 5-Year Yield-on-Cost % has ranged from 1.32 to 2.73 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 2.39, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.39, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current 5-Year Yield-on-Cost % of 2.73 is 14.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current 5-Year Yield-on-Cost % is 2.73, which is 74% above median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.14, compared to a current price of $0.75 — trading 34.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.73, which is 74% above median its 10-year median of 1.57 and 14.2% above the Medical Devices & Instruments industry median of 2.39. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For NIOX Group (CSSPF), the current 5-Year Yield-on-Cost % is 2.73 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 34.2% below its estimated GF Value™ of $1.14.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
5-Year Yield-on-Cost %: 2.73 (74% above median its 10-year median of 1.57)
GF Value™: $1.14 vs. price of $0.75 (34.2% below fair value)
Industry Position: 14.2% above the Medical Devices & Instruments median (#149 of 329)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 